Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.
暂无分享,去创建一个
[1] Y. Miyashita,et al. Clinical determination of the severity of metabolic syndrome: preheparin lipoprotein lipase mass as a new marker of metabolic syndrome. , 2005, Current medicinal chemistry. Cardiovascular and hematological agents.
[2] P. Scherer,et al. Erratum: Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes (Diabetes (2004) 53 (1621-1629)) , 2005 .
[3] P. Scherer,et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. , 2004, Diabetes.
[4] L. J. Hardies,et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.
[5] A. Festa,et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.
[6] H. Lochnan,et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. , 2003, Clinical therapeutics.
[7] F. Ashcroft,et al. Sulfonylurea stimulation of insulin secretion. , 2002, Diabetes.
[8] H. Gin,et al. Oral anti diabetic polychemotherapy in type 2 diabetes mellitus. , 2002, Diabetes & metabolism.
[9] J. Hardies,et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.
[10] J. S. St. Peter,et al. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. , 2002, Diabetes care.
[11] M. Matsuda,et al. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.
[12] T. Saruta,et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. , 2002, Metabolism: clinical and experimental.
[13] M. Stumvoll,et al. Glitazones: clinical effects and molecular mechanisms , 2002, Annals of medicine.
[14] U. Smith,et al. Pioglitazone: mechanism of action. , 2001, International journal of clinical practice. Supplement.
[15] Felicity Kaplan,et al. PPARs, Insulin Resistance and Type 2 Diabetes , 2001, Journal of cardiovascular risk.
[16] Wei Chen,et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. , 2001, Diabetes.
[17] M. Kipnes,et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. , 2001, The American journal of medicine.
[18] S. Halimi,et al. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. , 2000, Diabetes care.
[19] S. Aronoff,et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.
[20] H. Daida,et al. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome , 2000, Current opinion in lipidology.
[21] A. Harrower. Comparative Tolerability of Sulphonylureas in Diabetes Mellitus , 2000, Drug safety.
[22] B. Lowell. An Essential Regulator of Adipogenesis and Modulator of Fat Cell Function: PPARγ , 1999, Cell.
[23] Y. Seino,et al. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats. , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[24] R. Krauss,et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[25] Y. Matsuzawa,et al. [Insulin resistance syndrome, visceral fat syndrome]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.
[26] J. Auwerx,et al. Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.
[27] R. Krauss,et al. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.
[28] J. Tugwood,et al. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. , 1996, European journal of biochemistry.
[29] K. Shii,et al. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. , 1996, Biochemical and biophysical research communications.
[30] G. Dagenais,et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.
[31] L. N. Kaufman,et al. Pioglitazone attenuates diet-induced hypertension in rats. , 1995, Metabolism: clinical and experimental.
[32] M. Laakso,et al. Lipids and Lipoproteins Predicting Coronary Heart Disease Mortality and Morbidity in Patients With Non-insulin-dependent Diabetes , 1993 .
[33] J. Friedman,et al. Tackling a weighty problem , 1992, Cell.
[34] W C Willett,et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.
[35] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[36] Debbie L. Hahs-Vaughn,et al. Multiple Comparison Procedures , 2013 .
[37] L. Grossman. New solutions for type 2 diabetes mellitus: the role of pioglitazone. , 2002, PharmacoEconomics.
[38] P. Suwattee,et al. Effects of the Thiazolidinediones on Cardiovascular Risk Factors , 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[39] E. Bonora,et al. Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin S e n s i t i v i t y , 2000 .
[40] B. Lowell. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. , 1999, Cell.
[41] R. Krauss,et al. Nondenaturing polyacrylamide gradient gel electrophoresis. , 1986, Methods in enzymology.
[42] Peter Olson,et al. Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .